Business News

Capital One more bullish on Ideaya Biosciences after study update

Unity Biotechnology reports Q3 EPS ($1.36), consensus ($1.65)

Capital One analyst Zegbeh Jallah remains a buyer of Ideaya Biosciences after the company announced the initiation of a Phase 2 clinical study of darovasertib in the neoadjuvant and adjuvant uveal melanoma settings. The analyst says that while neoadjuvant or adjuvant use is not yet a part of the firm’s $29 price target valuation, it offers “major upside given the large market opportunity.” Ideaya’s “rapid progress” has made Capital One more bullish on the shares.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IDYA:

Click Here to Read the Full Original Article at TipRanks Financial Blog…